UCBT With FM-Based Reduced-Intensity Conditioning Improved Survival in Lymphoma
Researchers sought to determine whether UCBT with FM-based reduced-intensity conditioning would improve survival outcomes in patients with lymphoma.
Graft Vs Host Disease
Improved Outcomes Seen With Combined Cyclophosphamide and Antithymocyte Globulin in PBSCT
Researchers sought to determine if the combination of PTC-gamma and low-dose antithymocyte globulin could improve efficacy in patients who underwent haplo-PBSCT.
Itacitinib Monotherapy Appears Safe, Effective for Acute, Low-Risk Graft Vs Host Disease
Researchers sought to determine whether itacitinib would be an effective therapy for patients with low-risk, acute GVHD.
2-Year Nonrecurrence Linked With Improved Long-Term Survival With Haplo-SCT
Researchers sought to determine whether there could be a link between haplo-SCT and survival in patients with hematologic malignancies who remain disease free for 2 years.
Orca-T Improves Outcomes After Myeloablative Conditioning for Hematologic Malignancies
Researchers sought to determine whether Orca-T would improve outcomes for GVHD- and relapse-free survival after myeloablative conditioning.
Novel Haploidentical Bone Marrow Transplantation Approach Effective in Relapsed/Refractory Severe Aplastic Anemia
Researchers sought to determine whether a novel approach to haploidentical bone marrow transplantation would be effective in patients with aplastic anemia.
Disruption to Gut Microbiome Predictive of Acute GVHD Severity, Outcomes
Researchers sought to determine if patients’ fecal microbiome is associated with severity of GVHD and outcomes after allogeneic HCT.
GVHD Grade at Diagnosis Correlates With Disease Progression, Overall Survival
A multicenter study sought to determine the rate of progression to a higher grade among patients who develop acute GVHD after undergoing hematopoietic stem cell transplantation.
Imbruvica Approved for Pediatric Patients With Chronic Graft-vs-Host Disease
The approval was based on data from a phase 1/2 trial that included patients 1 year to less than 22 years of age with cGVHD after failure of 1 or more lines of systemic therapy.
Risk Factors for Clinical Outcomes and Poor Visual Prognosis in Chronic Ocular GVHD
Researchers sought to determine the clinical outcomes and visual prognosis for patients with ocular GVHD.
- Loading...
Loading...
Next post in General Hematology
Loading... 
Loading...